drugset / Trial / NCT06212076
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).
Timeline
- Start
- 2024-07-11
- Primary completion
- 2027-07-09
- Completion
- 2027-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPG1094 | Unknown | 200 mg | Oral |
| Subject | IPG1094 | Unknown | 250 mg | Oral |